in the absence of a submission from the holder of the marketing authorisation:
semaglutide tablet (Wegovy®) is not recommended for use within NHSScotland.
Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.
SMC has previously accepted semaglutide FlexTouch solution for injection in pre-filled pen (Wegovy®) for restricted use for this indication (SMC2497). This advice remains valid.
Download detailed advice365KB (PDF)
Medicine details
- Medicine name:
- semaglutide (Wegovy)
- SMC ID:
- SMC2988
- Indication:
As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity.- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 October 2026